Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPERIST: Perineural Injections for Chronic Post-traumatic Neuropathic Pain
NCT03009500Phase 3Completed
- Sponsor
- University Health Network
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection and methylprednisolone injection in Peripheral neuropathic pain (3 arms), sponsored by University Health Network. Primary endpoint: Numerical Rating Score for foot and ankle pain at 1 month. Started Jan 2017; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injectionmethylprednisolone injection
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT03009500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009500.